2 Reflections and Prospects

2 Reflections and Prospects

Chronic myelogenous leukemia is a neoplastic proliferative disease originating from multipotent hematopoietic stem cells. According to TCM theory, it is characterized by deficiency at the root and excess at the surface, with a mixture of deficiency and excess throughout the course of the disease. Heat, blood stasis, phlegm, and deficiency permeate the entire disease process. Professor Pei Zhengxue’s “Lanzhou Formula” is an effective prescription for treating hematological diseases, formulated based on his extensive clinical experience. This formula integrates strengthening the spleen and tonifying the kidneys, reinforcing righteous qi while eliminating pathogenic factors, balancing the root and the surface. Over several decades, the “Lanzhou Formula” has achieved satisfactory clinical results in treating CML, increasing remission rates, markedly improving symptoms and signs, enhancing patients’ quality of life, and reducing the toxic side effects of Western chemotherapy. The inception of this research was inspired by Professor Pei Zhengxue’s more than fifty years of clinical experience, fully embodying the idea that clinical experience guides clinical research and avoiding blind experimentation. This clinical study provides ideas and methods for using advanced modern medical technologies to explore and develop anti-hematological tumor formulas guided by traditional Chinese medicine theory. However, due to limitations in time and funding, further research has not yet been conducted on the impact of the “Lanzhou Formula” on the accelerated and blast phases of CML, nor on the specific pathways through which it induces apoptosis in leukemia cells. Future studies should make full use of new advances in modern science and technology to delve deeper into the mechanisms by which the “Lanzhou Formula” treats leukemia, explore Professor Pei Zhengxue’s thoughts and methods on integrating TCM and Western medicine to prevent and treat hematological diseases, and obtain more objective, microscopic scientific analysis of clinical prescriptions.

References

[1] Xiao Shiyong. Understanding and Treatment Overview of Chronic Myelogenous Leukemia in Traditional Chinese Medicine. Jiangxi Journal of Traditional Chinese Medicine, 1992, 23(6): 55.

[2] Wu Songkang. Syndrome Differentiation Treatment of Chronic Myelogenous Leukemia. Journal of Zhejiang College of Traditional Chinese Medicine, 1998, 22(5): 16.

[3] Hou Pihua and Liang Yijun. Insights and Treatment Experience Regarding Chronic Myelogenous Leukemia. Beijing Journal of Traditional Chinese Medicine, 1999, (2): 69–71.

[4] O'Dwyer ME, Mauro MJ, Druker BJ. Recent Advances in the Treatment of Chronic Myelogenous Leukemia [J]. Annual Review of Medicine, 2002, 53: 369–381.

[5] Carabasi MH. Cancer Investigation, 1993, 11: 408.

[6] Tang Lijun. Progress in Molecular Research Related to the Blast Phase of Chronic Myelogenous Leukemia. Foreign Medical Journal · Physiology, Pathology, and Clinical Sciences, 1999, 19(1): 48–50.

[7] Heisterkamp N et al. Nature, 1985, 315(6022): 758–761.

[8] Liu Qingping, She Ying, Su Xiulan et al. Study on Dehydrogenase Isoenzymes of Thymus and Spleen Lymphocytes in L615 Leukemic Mice. 1994, 3(2): 176–179.

[9] Verfaillie CM, Miller WJ, Boylan K et al. Selection of Benign Primitive Hematopoietic Progenitors in Chronic Myelogenous Leukemia Based on HLA-DR Antigen Expression. Blood, 1992, 79: 1003.

[10] Liu Huifang, Zheng Manlei, Shen Yikui. Clinical Analysis of 31 Cases of Pediatric Chronic Myelogenous Leukemia. Guangdong Medical Journal, 1996, 17(6): 382–383.

[11] Chen Guiting. Practical Integrated Diagnosis and Treatment of Traditional Chinese and Western Medicine. China Pharmaceutical Science and Technology Press, 1994: 3.

[12] O'Dwyer ME, Mauro MJ, Druker BJ. Recent Advances in the Treatment of Chronic Myelogenous Leukemia [J]. Annual Review of Medicine, 2002, 53: 369–381.

[13] Wang H, Cheng F, Cuenca A et al. Imatinib Mesylate (STI-571) Enhances Antigen-Presenting Cell Function and Overcomes Tumor-Induced CD4+ T-Cell Tolerance [J]. Blood, 2005, 105(3): 1135–1143.

[14] Liu Li and Liu Qiang. Non-myeloablative Haploidentical Hematopoietic Stem Cell Transplantation Combined with Gleevec Treatment for Chronic Myelogenous Leukemia. Clinical Hematology Journal, 2006, 19(1): 3–6.

[15] Zhang Zhinan and Shen Ti. Diagnostic and Therapeutic Standards for Hematological Diseases (Third Edition). Science Press, 2007: 134–135.

[16] Meng Fanyi, Sun Jing, Liu Qifa et al. Gleevec Treatment for Chronic Myelogenous Leukemia After Ph Chromosome Turn-Negative Followed by Autologous Peripheral Blood Stem Cell Transplantation. 303.

Research on Pei Zhengxue’s Series of Formulas and Medications

Results. First Military Medical University Journal, 2003, 23(12): 1301–1306

[17] Yao Xiaojian and Liu Chunxia. Application of Imatinib Mesylate Before Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia. Journal of Clinical Hematology, 2005, 18(3): 154–158

[18] Li Huimin, Shi Lan, Wen Bo et al. One Case of Gleevec Combined with Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplantation for Acute Blast Phase Chronic Myelogenous Leukemia. Journal of Leukemia & Lymphoma, 2004, 13(3): 192

[19] Miao Tusheng. Clinical Observation of Anti-Leukemia Treatment for Chronic Myelogenous Leukemia. Zhejiang Journal of Traditional Chinese Medicine, 1997, 32(6): 245–246

[20] Zhong Lu. Progress in Treatment of Chronic Myelogenous Leukemia. Chinese Journal of Hematology, 2000, 9(4): 252–254

[21] Zhang Zhinan and Pan Huazhen. Apoptosis and Hematological Diseases. Chinese Journal of Hematology, 1996, 17(5): 270

[22] Zang Yunhua and Li Zhen. Recent Status of Research on Traditional Chinese Medicine Inducing Apoptosis in Leukemia Cells. Shandong University of Traditional Chinese Medicine Journal, 2002, 26(7): 312–314

[23] Yao Bo, Guo Mei, Jiao Huaiyuan et al. Chronic Myeloid Leukemia Ph Chromosome Analysis and bcr/abl mRNA Detection. Chinese Journal of Hematology, 1999, 20(3): 137–139

[24] Pei Zhengxue. Practical Internal Medicine Combining Traditional Chinese and Western Medicine. Lanzhou: Gansu Science and Technology Press, 2010: 548–557

[25] Pei Zhengxue. Commentary on Xuezheng Lun. Lanzhou: Gansu Science and Technology Press, 2008: 100–104

[26] Pei Zhengxue. Collection of Pei Zhengxue’s Medical Talks and Case Records. Lanzhou: Gansu Science and Technology Press, 2004: 25–27

[27] Xi Xiaoxian. Discussion on the Mechanism of Traditional Chinese Medicine Inducing Tumor Cell Apoptosis. Shanxi University of Traditional Chinese Medicine Journal, 1999, 22(5): 62

[28] Pei Zhengxue. Collection of Pei Zhengxue’s Medical Experience. Lanzhou: Gansu Science and Technology Press, 2003: 32–34

[29] Li Junshan, Zhang Dan, Dong Jun et al. Effect of Qi-Tonifying and Yin-Nourishing Formulas on Leukemia Cell Apoptosis. Shandong University of Traditional Chinese Medicine Journal, 2000, 24(4): 305

[30] Xie Zhizhong. Effect of Total Saponins from Gynostemma pentaphyllum and Chemotherapy Drugs on the Proliferation of Cultured Chronic Myeloid Blast Cell Lines. Hengyang Medical College Journal, 1998, 26(1): 10–12

[31] Xu Jianhua, Zhao Rong, Ke Yue Ru et al. Effect of Curcumin on Human Leukemia Cell Apoptosis. Chinese Herbal Pharmacology and Clinical Practice, 1998, 14(6): 22

[32] Zhao Xiaogang. Clinical Analysis of 30 Cases of Chronic Myelogenous Leukemia Treated with 713. Chinese Journal of Traditional Chinese Medicine, 1997, (1): 24

---

Research on Pei Zhengxue’s Series of Formulas and Medications